Canaccord Genuity Maintains a 'Hold' on Allos Therapeutics (ALTH); Updating Growth Outlook
Tweet
Share
E-mailGet Alerts ALTH Hot Sheet
Price: $1.84 --0%
Rating Summary:
0 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Allos Therapeutics (NASDAQ: ALTH) price target of $1.50.
Analyst, George Farmer, said, "We maintain our rating on ALTH shares on our low growth expectations for Folotyn in relapsed/refractory peripheral T-cell lymphoma (PTCL)...ALTH issued 2012 Folotyn sales guidance of $50-55M, representing 16-28% growth over preannounced $43.1M in 2011 sales ex-infrequent items. We see guidance as somewhat aggressive given a flat 2011 quarterly trajectory of $10.9/11.0/10.2/11.0M. While mngmt cites growth drivers such as marketing effort focus and greater treatment option awareness, we look for signals of quarterly sales acceleration before adjusting our $42.3M 2012 estimate."
"We estimate 2012-end cash of $62M, below guided $74-78M, based on 2011-
end cash of $98M and our lower-than-guided product sales outlook."
For an analyst ratings summary and ratings history on Allos Therapeutics click here. For more ratings news on Allos Therapeutics click here.
Shares of Allos Therapeutics closed at $1.42 yesterday.
Analyst, George Farmer, said, "We maintain our rating on ALTH shares on our low growth expectations for Folotyn in relapsed/refractory peripheral T-cell lymphoma (PTCL)...ALTH issued 2012 Folotyn sales guidance of $50-55M, representing 16-28% growth over preannounced $43.1M in 2011 sales ex-infrequent items. We see guidance as somewhat aggressive given a flat 2011 quarterly trajectory of $10.9/11.0/10.2/11.0M. While mngmt cites growth drivers such as marketing effort focus and greater treatment option awareness, we look for signals of quarterly sales acceleration before adjusting our $42.3M 2012 estimate."
"We estimate 2012-end cash of $62M, below guided $74-78M, based on 2011-
end cash of $98M and our lower-than-guided product sales outlook."
For an analyst ratings summary and ratings history on Allos Therapeutics click here. For more ratings news on Allos Therapeutics click here.
Shares of Allos Therapeutics closed at $1.42 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- UBS Reiterates Buy Rating on HF Sinclair (DINO)
- New Street Research Upgrades Micron Technology (MU) to Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
